Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Lee, I.; Constantinescu, S.; Gillespie, A.; Swami, A.; Birkenbach, M.; Leech, S.; Silva, P.; Karachristos, A.; Daller, J.A.; Sifontis, N.M.
Clinical Transplants 2009: 425-429
2009
ISSN/ISBN: 0890-9016 PMID: 20524309 Document Number: 633982
Document emailed within 1 workday
Related Documents
Hardinger, K.L.; Alford, K.; Murillo, D. 2009: Bortezomib for acute humoral rejection in two repeat transplant recipients Clinical Transplants 2009: 479-483Wiesner, R.H.; Porayko, M.K.; Wahlstrom, H.E.; Gores, G.J.; Kamath, P.S.; Hay, J.E.; Krom, R.A. 1993: Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection Transplantation Proceedings 25(2): 1791-1793
Lubetzky, M.; Auli, M.J.; Walker, J.; Leeser, D.; Kapur, S.; Hartono, C.; Dadhania, D. 2010: Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection Clinical Transplants 2010: 437-440
Blanco, A.; Gómez-Carrasco, J.A. 1989: Cellular and humoral mechanisms in graft rejection Anales Espanoles de Pediatria 31(Suppl 39): 123-126
Hardinger, K.L.; Alford, K.; Murillo, D. 2010: Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience Clinical Transplants 2010: 429-436
Bryan, B.A.; Henry, M.L.; Ferguson, R.M. 1992: Renal xenografts perfused ex vivo require both humoral and cellular components to undergo hyperacute rejection Transplantation Proceedings 24(2): 609
Knosalla, C.; Grauhan, O.; Muller, J.; Pfitzmann, R.; Fietze, E.; Cohnert, T.; Volk, H.D.; Hetzer, R. 2000: Intramyocardial electrogram recordings (IMEG) for diagnosis of cellular and humoral mediated cardiac allograft rejection Annals of Thoracic and Cardiovascular Surgery: Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 6(2): 89-94
Baldamus, C.A. 1973: Rejection and rejection protection of transplants by humoral antibodies Verhandlungen der Deutschen Gesellschaft für Innere Medizin 79: 585-588
Wong, W.; Lee, R-Ann.; Saidman, S.L.; Smith, R.Neal.; Zorn, E. 2009: Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports Clinical Transplants 2009: 401-405
Schwaiger, E.; Regele, H.; Wahrmann, M.; Werzowa, J.; Haidbauer, B.; Schmidt, A.; Böhmig, G.A. 2010: Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report Clinical Transplants 2010: 391-396
Stein, G.; Henn, W.; von Laue, H.; Berg, P. 1998: Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy European Journal of Medical Research 3(4): 194-202
Winde, G.; Dietl, K.H.; Raidt, H.; Buchholz, B.; Lison, A.E.; Bünte, H. 1988: Use of Orthoclone OKT3 as treatment of acute renal allograft rejection and as first-line therapy in kidney transplantation Transplantation Proceedings 20(5 Suppl 6: 87-89
Martín Mola, E.; Cabarcos Cazón, A.; Imizcoz, J.L.; Pérez Miranda, M. 1980: Humoral and cellular immunopathology of rheumatoid arthritis. II. Quantitative cellular immunity Revista de Medicina de la Universidad de Navarra 24(4): 43-48
Leyva, S.; Marino-Vázquez, L.A.; Reyes-Loaeza, J.A.; Vega, O.; Uribe-Uribe, N.; Alberú, J.; Morales-Buenrostro, L.E. 2009: Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City Clinical Transplants 2009: 369-376
Jordan, S.C.; Quartel, A.W.; Czer, L.S.; Admon, D.; Chen, G.; Fishbein, M.C.; Schwieger, J.; Steiner, R.W.; Davis, C.; Tyan, D.B. 1998: Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action Transplantation 66(6): 800-805
Fu, Y.-b.; Sun, Q.-x.; Meng, F.-y.; Xie, J.; Zhou, G.-b. 2006: Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor Zhonghua Yi Xue Za Zhi 86(34): 2413-2416
Costanzo-Nordin, M.R.; McManus, B.M.; Wilson, J.E.; O'Sullivan, E.J.; Hubbell, E.A.; Robinson, J.A. 1993: Efficacy of photopheresis in the rescue therapy of acute cellular rejection in human heart allografts: a preliminary clinical and immunopathologic report Transplantation Proceedings 25(1 Pt 2): 881-883
Gaweco, A.S.; Otto, G.; Otto, H.F.; Meuer, S.; Geisse, T.; Hofmann, W.J. 1995: Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression Transplantation Proceedings 27(1): 1152-1154
Slatinská, J.; Honsová, E.; Lyerová, L.; Slavcev, A.; Viklický, O. 2007: Acute humoral rejection of renal transplant Vnitrni Lekarstvi 53(3): 246-247; 249-252
Sun, Q.; Li, L. 2006: Graft loss associated with late humoral rejection after renal transplantation Clinical Transplants 2006: 521-525